Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females, ≥ 18 years of age at the time of signing the informed consent document~2. Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening~   a. Have moderate to severe plaque psoriasis at Screening and Baseline~3. Must meet all laboratory criteria~4. Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception as described by the Study Doctor while on study medication and for at least 28 days after taking the last dose of study medication~5. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural \[animal\] membrane \[eg, polyurethane\]) while on study medication and for a least 28 days after the last dose of study medication.~Exclusion Criteria:~1. Other than psoriasis, history of any clinically significant (as determined by the Investigator) or other major uncontrolled disease.~2. Pregnant or breast feeding~3. History of allergy to any component of the study drug~4. Hepatitis B surface antigen positive at Screening~5. Anti-hepatitis C antibody positive at Screening~6. Active tuberculosis (TB) or a history of incompletely treated TB~7. Clinically significant abnormality on 12-Lead ECG at Screening~8. Clinically significant abnormal chest x-ray~9. History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency~10. Active substance abuse or a history of substance abuse within 6 months prior to Screening~11. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening~12. Malignancy or history of malignancy (except for treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas and treated \[ie, cured\] cervical intraepithelial neoplasia \[CIN\] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years)~13. Psoriasis flare or rebound within 4 weeks prior to Screening~14. Evidence of skin conditions that would interfere with clinical assessments~15. Topical therapy within 2 weeks of randomization~16. Systemic therapy for psoriasis within 4 weeks prior to randomization~17. Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)~18. Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization~19. Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization~20. Use of any investigational drug within 4 weeks prior to randomization~21. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources~22. Prior treatment with apremilast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast (Type: EXPERIMENTAL): Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (\<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( \< PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).

Based on this trial design, predict the completion outcome and termination type (if applicable).